EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kenai Therapeutics","sponsor":"Alaska Permanent Fund Corporation","pharmaFlowCategory":"D","amount":"$82.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Kenai Therapeutics

    Menu

    Kenai Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kenai Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

              Details:

              The financed Proceeds will be used for the clinical development of the lead candidate, RNDP-001, an iPSC-derived, allogeneic dopamine progenitor cell therapy. Which is currently evaluated in the preclinical studies for the treatment of Parkinson’s disease.

              Lead Product(s): RNDP-001

              Therapeutic Area: Neurology Product Name: RNDP-001

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Alaska Permanent Fund Corporation

              Deal Size: $82.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing February 29, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              With Fermion, start the journey of your innovative API.
              Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
              Post Enquiry
              POST ENQUIRY